Component
Free D-aspartate in human dorsolateral prefrontal cortex
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Schizophrenia DLPFC samples had approximately 30% lower free D-aspartate and 25% higher DDO activity; the D-aspartate reduction was not detected in hippocampus.
Experimental context and source evidence
- availability_state
- biomarker_context Imported condition classification; unverified.
- evidence_access
- Primary full text
- experimental_model
- Human postmortem case-control study.
- limitations
- Not a dietary deficiency diagnosis, proof of disease cause, or a supplementation trial.
- nutrient_topic
- D-Aspartate collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · D-Aspartate
- plain_language
- The measured difference was local to a brain region.
- primary_references
- Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients. · 2017 · https://pubmed.ncbi.nlm.nih.gov/28560262/ · DOI 10.1038/s41537-017-0015-7
- trigger_kind
- biomarker_context Imported condition classification; unverified.
D-Aspartate: synthesis, clearance, neural and endocrine mechanisms (2026-09-19) · lines 304–310
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human postmortem case-control study. · source_derived_draft · unverified_draft
## d-aspartate-human-low-dasp The measured difference was local to a brain region. Schizophrenia DLPFC samples had approximately 30% lower free D-aspartate and 25% higher DDO activity; the D-aspartate reduction was not detected in hippocampus. Model: Human postmortem case-control study. Limitations: Not a dietary deficiency diagnosis, proof of disease cause, or a supplementation trial. Evidence access: Primary full text Decreased free d-aspartate levels are linked to enhanced d-aspartate oxidase activity in the dorsolateral prefrontal cortex of schizophrenia patients. · 2017 · https://pubmed.ncbi.nlm.nih.gov/28560262/ · DOI 10.1038/s41537-017-0015-7
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.